<DOC>
	<DOCNO>NCT00648622</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Mylan 's carvedilol 12.5 mg tablet GSK 's Coreg® 12.5 mg tablet follow single , oral 12.5 mg ( 1 x 12.5 mg ) dose administer fed condition .</brief_summary>
	<brief_title>Fed Study Carvedilol Tablets 12.5 mg Coreg® Tablets 12.5 mg</brief_title>
	<detailed_description />
	<mesh_term>Carvedilol</mesh_term>
	<criteria>1 . Age : 18 year old . 2 . Sex : Male and/or nonpregnant , nonlactating female . 1 . Women childbearing potential must negative serum beta human chorionic gonadotropin ( betaHCG ) pregnancy test perform within 14 day prior start study even prior dose administration . If dose schedule weekend , HCG pregnancy test give within 48 hour prior dose study period . An additional serum ( betaHCG ) pregnancy test perform upon completion study . 2 . Women childbearing potential must practice abstinence use acceptable form contraception throughout duration study . No hormonal contraceptive hormone replacement therapy permit study . Acceptable form contraception include follow : 1. intrauterine device place least 3 month prior start study remain place study period , 2. barrier method contain use conjunction spermicidal agent , 3. surgical sterility ( tubal ligation , oophorectomy hysterectomy ) postmenopausal accompany document postmenopausal course least one year . 3 . During course study , study screen study exit include washout period , woman childbearing potential must use spermicide contain barrier method contraception addition current contraceptive device . This advice document informed consent form . 3 . Weight : At least 60 kg ( 132 lb ) men 48 kg ( 106 lb ) woman subject within 15 % Ideal Body Weight ( IBW ) , reference Table `` Desirable Weights Adults '' Metropolitan Life Insurance Company , 1999 ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 4 . All subject judge normal healthy prestudy medical evaluation ( physical examination , laboratory evaluation , hepatitis B hepatitis C test , HIV test , 12lead ECG , urine drug screen include amphetamine , barbiturate , benzodiazepine , cannabinoid , cocaine , opiate screen , phencyclidine , methadone ) perform within 14 day initial dose study medication . 1 . Institutionalized subject use . 2 . Social Habits : 1 . Use tobacco product within 1 year start study . 2 . Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . 3 . Ingestion vitamins herbal product within 7 day prior initial dose study medication . 4 . Any recent , significant change dietary exercise habit . 5 . A positive test drug include urine drug screen . 6 . History drug and/or alcohol abuse . 3 . Medications : 1 . Use prescription overthecounter ( OTC ) medication within 14 day prior initial dose study medication . 2 . Use hormonal contraceptive hormone replacement therapy within 3 month prior study medication dosing . 3 . Use medication know alter hepatic enzyme activity within 28 day prior initial dose study medication . 4 . Diseases : 1 . History significant cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic disease . 2 . Acute illness time either prestudy medical evaluation dosing . 3 . A positive HIV , hepatitis B , hepatitis C test . 5 . Abnormal clinically significant laboratory test result : 1 . Clinically significant deviation Guide Clinically Relevant Abnormalities ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 2 . Abnormal clinically relevant ECG tracing . 6 . Donation loss significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication . 7 . Subjects receive investigational drug within 30 day prior initial dose study medication . 8 . Allergy hypersensitivity carvedilol component formulation . 9 . History difficulty swallow , gastrointestinal disease could affect drug absorption . 10 . Bradycardia le 50 beats/minute supine position , measure ECG , screen visit prior Period I Day 1 dosing . 11 . Sitting pulse rate le 60 beat per minute sit systolic blood pressure le 90 great 140 sit diastolic blood pressure le 60 great 90 fiveminute rest period Screening Visit prior Period I Day 1 dosing . 12 . Consumption grapefruit grapefruit containing product within 7 day drug administration . 13 . History asthma pulmonary problem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>